Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Brief Summary: To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.


Options:
A: Arm Label: Finerenone (BAY94-8862) (1.25 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(2.5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(7.5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862) (10 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862) (15 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(20 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): Finerenone (BAY94-8862) (1.25 mg), Finerenone (BAY94-8862) (10 mg), Finerenone (BAY94-8862) (15 mg), Finerenone (BAY94-8862)(2.5 mg), Finerenone (BAY94-8862)(20 mg), Finerenone (BAY94-8862)(5 mg), Finerenone (BAY94-8862)(7.5 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
C: Arm Label: addition of spironolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): addition of spironolactone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 5 | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Arm 6

Answer: A